ストックスクリーナーアプリを入手
0.74
1.11%
-0.0083
アフターアワーズ：
.71
-0.03
-4.05%
前日終値:
$0.7483
開ける：
$0.7333
24時間の取引高:
12,699
Relative Volume:
0.14
時価総額：
$2.45M
収益：
$4.51M
当期純損益:
$-7.66M
株価収益率:
-0.1959
EPS:
-3.778
ネットキャッシュフロー:
$-7.51M
1週間 パフォーマンス:
+5.56%
1か月 パフォーマンス:
+9.14%
6か月 パフォーマンス:
-57.23%
1年 パフォーマンス:
-75.50%
1日の値動き範囲:
$0.7253
$0.765
1週間の範囲:
$0.70
$0.81
52週間の値動き範囲:
$0.575
$7.98
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
名前
Inmed Pharmaceuticals Inc
セクター
電話
(604) 669-7207
住所
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
0.74 | 2.48M | 4.51M | -7.66M | -7.51M | -3.778 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Inmed Pharmaceuticals Inc (INM) 最新ニュース
InMed Pharmaceuticals Reprices Investment Options to Attract Capital - TipRanks
InMed Pharmaceuticals Amends Preferred Investment Options - TMX Newsfile
InMed Pharmaceuticals Reprices Sabby and Wainwright Investment Options to $0.80 - TradingView
[8-K] InMed Pharmaceuticals Inc. Reports Material Event - Stock Titan
Sabby, Wainwright option deals reset InMed exercise prices to $0.80 - Stock Titan
Is InMed (INM) stock gaining momentum (Smart Money Flows) 2026-04-18Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Fund Flows: Is InMed Pharmaceuticals Inc in a long term uptrend2026 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Income Plays: Is InMed Pharmaceuticals Inc in a long term uptrend2026 Market Trends & Verified Momentum Stock Alerts - baoquankhu1.vn
InMed Pharmaceuticals Inc. Files Form 8-K Current Report with SEC – Company Information, Nasdaq Listing, and Legal Opinion Included - Minichart
Price performance - Yahoo Finance Singapore
Published on: 2026-04-05 13:17:10 - baoquankhu1.vn
InMed Pharmaceuticals files prospectus supplement for at-the-market share offering - Investing.com
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing - TipRanks
InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement - TradingView — Track All Markets
InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf - Stock Titan
InMed Pharmaceuticals (NASDAQ: INM) files $1.21M ATM offering with 3.0% fee - Stock Titan
[EFFECT] InMed Pharmaceuticals Inc. SEC Filing - Stock Titan
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
InMed receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com Australia
InMed warned by Nasdaq over minimum bid price non-compliance - TipRanks
InMed Pharmaceuticals Notified of Nasdaq Non-Compliance with $1 Minimum Bid Price Rule - geneonline.com
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Investing News Network
InMed receives Nasdaq minimum bid price deficiency notice - Investing.com
InMed Pharma gets Nasdaq non-compliance notice - MSN
InMed Pharmaceuticals Inc.Common Shares (NQ: INM - The Chronicle-Journal
InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12 - Minichart
InMed reports preclinical data on Alzheimer’s drug candidate By Investing.com - Investing.com Australia
InMed Pharmaceuticals Inc. (INM) Stock: Shows Promising Anti-Inflammatory Effects in 3D Brain Organoid Study - parameter.io
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with N - GuruFocus
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Investing News Network
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate - TipRanks
InMed reports preclinical data on Alzheimer’s drug candidate - Investing.com
InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC). - Bitget
InMed (NASDAQ: INM) reports INM-901 organoid data, targets Phase 1 in 2027 - Stock Titan
Aug Decliners: Can InMed Pharmaceuticals Inc outperform under higher oil pricesWeekly Market Outlook & Low Drawdown Trading Strategies - baoquankhu1.vn
[S-3] InMed Pharmaceuticals Inc. Shelf Registration Statement - Stock Titan
Aug Weekly: Can InMed Pharmaceuticals Inc be the next market leaderBear Alert & Accurate Entry/Exit Alerts - baoquankhu1.vn
Ideas Watch: Can InMed Pharmaceuticals Inc be the next market leader2026 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Published on: 2026-03-17 19:00:00 - baoquankhu1.vn
CEO Moves: Will InMed Pharmaceuticals Inc stock go up in YEAR2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
InMed Pharmaceuticals Advances INM-901 for Alzheimer’s and INM-089 for Macular Degeneration with FDA Engagement Planned for 2026-2027 1 - Minichart
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
InMed Pharmaceuticals (INM) Sets 2026 Development Goals - gurufocus.com
InMed Provides Update on Pharmaceutical Development ProgramsAdvancing Lead Drug Candidates Towards IND and Clinical Trial - Investing News Network
InMed outlines 2026 development plans for lead programs - TipRanks
InMed Provides 2026 Development Outlook; Targets FDA pre-IND for INM-901 and Phase 1 in 2027 - TradingView
InMed (INM) sets 2026 goals for Alzheimer’s and eye-disease drug programs - Stock Titan
InMed's 2026 push to bring Alzheimer's, eye drug candidates to human testing - Stock Titan
Can InMed Pharmaceuticals Inc reach all time highs this yearJuly 2025 Technicals & Weekly Momentum Picks - baoquankhu1.vn
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Investing News Network
Inmed Pharmaceuticals Inc (INM) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):